The role of pharmacoeconomic evaluations in disease management

PharmacoEconomics

Volumn 14, Issue 1, 1998, Pages 11-17

  Chang, Kenneth ^a   Nash, David ^a,b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; DISEASE MANAGEMENT; EMERGENCY TREATMENT; HEALTH ECONOMICS; HOSPITAL CARE; INFORMATION SYSTEM; OUTCOMES RESEARCH; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION;

COST CONTROL; DISEASE MANAGEMENT; ECONOMICS, PHARMACEUTICAL; HUMANS;

EID: 0031852473     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814010-00002     Document Type: Review

References (17)

1. Wynn P. The role of physicians in disease management. Manage Care 1996; 5 (10): 19-22
2. Pasternak DP, Harris JM. Does disease management work? Physician Exec 1996; 22 (12): 28-32
3. Patterson R. Disease management: case review, Fall 1995
4. Muir L. Disease management: hospitals and health networks. Hosp Health Netw 1997; 71 (11): 24-30
5. Zablocki E. Using disease state management to coordinate care across the continuum. Qual Lett Healthe Lead 1995; 7 (9): 2-10
6. Ginsberg B. Preliminary results of a disease management program for diabetes. J Clin Outcomes Manage 1996; 3 (4): 45-51
7. Rajagopalan R, Kallal J, Fowler J. Practical issues in conducting pharmacoeconomic studies. Clin Ther 1996; 18 (6): 1298-305
8. Johnson N, Nash D, editors. The role of pharmacoeconomics in outcomes management. Chicago: American Hospital Publishing, 1996
9. Roglieri JL, Futterman R, McDonough K, et al. Disease management interventions to improve outcomes in congestive heart failure. Am J Manage Care 1997; 3 (12): 1831-9
10. Tauke J, Goldstein S, Gheorghiade M. Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of angiotensin Converting Enzyme) trials. Prog Cardiovasc Dis; 37 (1): 49-58
11. Bischof R, Nash D, Lewis J. The economics of drug therapy. In: Friedman G, Jacobson ED. McCallum RW, et al., editors. Gastrointestinal pharmacology and therapeutics. Philadelphia: Lippincott-Raven, 1997: 743-58
12. Rittenhouse B. Is there a need for standardization of methods in economic evaluations of medicines? Med Care 1996; 34 (12): DS13-22
13. Drummond M. The future of pharmacoeconomics: bridging science and practice. Clin Ther 1996; 18 (5): 969-78
14. Engstrom P. Pharmacoeconomic studies: they're not all created equal. Manage Care Pharm Prac 1995; 2 (3): 30-33
15. Moyer P. Drug research at MCO's. Manage Healthcare 1995; Suppl. I: S20-47
16. Hillman AI, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 325 (19): 1384-5
17. McGhan W. Ist annual international meeting of the Association for Pharmacoeconomics and Outcomes Research. Clin Ther 1996; 18 Suppl. A: 1-4